We are Sorry, This Page doesn't Exist
Tesla"s Robotaxi Plans: Potential Threat Or Future Partner For Uber?
Post from BofA reiterates Buy rating on Uber with $91 price target. Expecting strong Q1 results, potential partnership with Tesla in long term. L.....»»
AstraZeneca admits its Covid vaccine can cause rare side effect in court documents for first time
AstraZeneca admits its Covid vaccine can cause rare side effect in court documents for first time.....»»
4 Analysts Have This To Say About Autoliv
Latest Rating.....»»
AstraZeneca admits for first time in court documents its Covid vaccine can cause rare side effect
AstraZeneca admits for first time in court documents its Covid vaccine can cause rare side effect.....»»
AstraZeneca admits for first time its Covid vaccine can cause rare side effect
AstraZeneca admits for first time its Covid vaccine can cause rare side effect.....»»
Boeing Isn"t Junk Status — Yet: Moody"s Outlook On Aircraft Maker Goes Negative
Boeing is still considered "investment-grade," but a lower rating would mean that it's a "speculative" play — "junk" status. read more.....»»
Boeing Dumps After Moody"s Downgrade To One Notch Above "Junk"
Boeing Dumps After Moody's Downgrade To One Notch Above 'Junk' Update (1420ET): Moody’s Ratings downgraded Boeing’s credit rating to Baa3 from Baa2 - just on.....»»
IBM"s Moment Of Truth As Earnings Expected To Impress With Strong AI Influence, Analyst Says
IBM (NYSE:IBM) reports Q1 earnings on April 24, with EPS of $1.59 and $14.6B in revenues expected. Stock up 45% in past year. BofA analyst maintains Buy rating and $220 price target. Latest Rati.....»»
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. Latest Ratings for INCY DateFirmActio.....»»
Insights Into Astrazeneca Q1: Wall Street Projections for Key Metrics
In its upcoming report, Astrazeneca (NYSE: AZ.....»»
"Gross Abuse Of Power" - Two SEC Lawyers Resign After Judge"s Rebuke In Anti-Crypto Case
"Gross Abuse Of Power" - Two SEC Lawyers Resign After Judge's Rebuke In Anti-Crypto Case Score o.....»»
Microsoft Analyst Says Q3 Print From "Favorite AI Superstar" May Boost Bullish Outlook, Sees Azure Raking In Whopping $76B Annual Revenue
Piper Sandler analyst Brent Bracelin maintained an Overweight rating and a $455 price target for the stock. .....»»
Money Talk with Liz Weston: Can my credit score really be marred over $20?
A missed $20 credit card payment hurt a responsible borrower's credit score. Was there anything to be done?A missed $20 credit card payment hurt a responsible borrower's credit score. Was there anything to be done?.....»»
Looking At AstraZeneca"s Recent Unusual Options Activity
read more.....»»
Two Tampa restaurants win Michelin stars for the first time
For the third year in a row, not a single Florida restaurant received three stars, the guide's highest rating......»»
Trump Media Vs. Reddit — Analyzing The Showdown Of Social Media Giants
Analyst sentiment leans cautiously towards Trump Media; Reddit garners optimism, boasting a consensus Buy rating with a 23.55% upside potential. read more.....»»
Discover Financial Faces Concerns Over Remediation Reserve, Analysts Caution Despite Q1 Sales Growth
Discover Financial Services faces scrutiny over remediation reserves as analysts express caution despite strong Q1 revenue growth. Latest Rating.....»»
New Milwaukee pro soccer team may score partnership with top German club: Bloomberg
Bloomberg reported that Eintracht Frankfurt is in talks with the fledgling Milwaukee team led by Milwaukee-area entrepreneur Jim Kacmarcik......»»
Super Micro Computer To Rally Around 70%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Latest Ratings for SMCI DateFirmActionFr.....»»
AstraZeneca"s Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival improvement. read more.....»»